Goldman Sachs leads $132 million investment in cancer start-up - Alterome

About
Overview Leadership The A-team BOD Advisors Investors Contact
Science
Approach AKT-driven cancers KRAS-driven cancers
Pipeline
Overview Tanerasertib (ALTA2618): AKT1 E17K ALTA3263: KRAS
News
Careers
Overview Mission & values Benefits Open positions Corporate responsibility

Goldman Sachs leads $132 million investment in cancer start-up

Contact us

Alterome Therapeutics
13480 Evening Creek Drive North
Suite 450
San Diego, CA 92128

General information
info@alterome.com

Clinical trials
clinical.trials@alterome.com

Privacy Policy Terms of Use

© 2026 Alterome Therapeutics.
All rights reserved.